MGO Methylglyoxal
Description: <b><a href="https://en.wikipedia.org/wiki/Methylglyoxal">Methylglyoxal</b></a> is a reduced derivative of pyruvic acid that is produced by glycolysis and other metabolic pathways. It is involved in the formation of advanced glycation end products, DNA damage, and diabetes complications.<br>
<br>
-Methylglyoxal is specifically inhibits OXPHOS in cancer cells ?<br>
-Methylglyoxal in cancer cells inhibits GAPDH, an essential enzyme acting in the glycolsis pathway. GAPDH inhibition depletes ATP profoundly depriving the cancer cells of energy. <br>
-Activator of GABA A receptor<br>
<br>
<a href="https://www.cancertreatmentsresearch.com/methilglyoxal/" >Some research may indicate it can promote cancer growth.</a><br>
<br>
Research Dose: (30-40mg/day) 7.5mg/kg 4 times/day? (plus 400mg Vit C) + VitB complex twice/day <br>
-Combine with curcumin(8g/d)?<br>
<br>
Combine with:<br>
Chitosan?<br>
Creatine (30-60 mins before)<br>
GLO1 inhibitors (Naringin, Curcumin)<br>
Nrf2 inhibitors: (ex Ascorbic Acid)<br>
GABA supplementation<br>
Metformin?<br>
<br>
Avoid combination with DCA?<br>
<br>
Sources:
<a href="https://www.scbt.com/p/methylglyoxal-solution-78-98-8" >Western or Chinese chemical suppliers under CAS number 78-98-8 </a> <br>
<p><b>Methylglyoxal</b> — Methylglyoxal (MGO; MG; pyruvaldehyde; 2-oxopropanal) is a highly reactive endogenous α-oxoaldehyde/dicarbonyl formed primarily from spontaneous degradation of glycolytic triose phosphates. It is a normal metabolic intermediate rather than an approved anticancer drug. MGO reacts rapidly with arginine, lysine, cysteine, proteins and DNA, producing advanced glycation end products and dicarbonyl stress. In cancer biology it has a concentration-dependent dual role: chronic modest elevation may support inflammatory/glycation-associated tumor biology, whereas sufficiently high intracellular MGO causes metabolic failure, mitochondrial dysfunction, oxidative stress, DNA/protein damage and apoptosis. Cancer cells frequently compensate by increasing glyoxalase-1 (GLO1), making the MGO-GLO1 axis a potential metabolic vulnerability.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>GLO1/glyoxalase-system overload or inhibition causes intracellular MGO accumulation and cytotoxic dicarbonyl stress; GLO1 overexpression is common in highly glycolytic tumors and can confer resistance to MGO stress.</li>
<li>Glycolytic inhibition, particularly modification/inactivation of GAPDH, suppresses glycolytic flux and contributes to ATP depletion.</li>
<li>Mitochondrial respiratory inhibition, including inhibition of respiratory complex I in several malignant-cell models, further decreases ATP production and promotes mitochondrial dysfunction.</li>
<li>ROS generation and oxidative stress trigger mitochondrial apoptosis, including mitochondrial membrane dysfunction, cytochrome-c release, Bax activation, Bcl-2 suppression and caspase signaling.</li>
<li>Protein and DNA glycation/adduct formation produces proteotoxic, replication and genotoxic stress at sufficiently high exposure.</li>
<li>PI3K/AKT and NF-κB survival signaling can be suppressed during high-MGO cytotoxic exposure in cancer models.</li>
<li>At lower or chronic concentrations, MGO-derived AGEs can activate RAGE, NF-κB, MAPK and inflammatory signaling; this provides a potentially pro-tumorigenic counter-effect distinct from the high-dose cytotoxic mechanism.</li>
<li>MGO is an endogenous partial agonist of neuronal GABA-A receptors, but this is primarily a neurophysiological effect and is not a central anticancer mechanism.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Free MGO is highly reactive and rapidly detoxified, principally through the glutathione-dependent GLO1/GLO2 system to D-lactate. Modern analytical studies generally place normal circulating free MGO in the submicromolar range, approximately 0.06–0.25 µM in well-controlled measurements, with intracellular concentrations commonly estimated in the low-micromolar range. Consequently, systemic exposure to orally administered MGO is constrained by rapid chemical reaction, metabolism and tissue detoxification; plasma concentration is not expected to track administered dose in a simple linear fashion.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many anticancer experiments use tens of micromolar through millimolar MGO, far above normal free plasma concentrations. Therefore, direct high-concentration MGO cytotoxicity demonstrated in vitro cannot be assumed achievable safely throughout human tumors after oral administration. The more translationally plausible strategy is currently manipulation of endogenous MGO accumulation through GLO1 or related metabolic vulnerabilities rather than attempting to maintain high circulating MGO concentrations.</p>
<p><b>Clinical evidence status:</b> Preclinical evidence is substantial for MGO-induced cancer-cell metabolic stress and apoptosis, with cell-culture and animal tumor studies supporting antitumor activity. Limited human treatment reports involving MGO-based formulations have been published, but they do not constitute modern randomized controlled evidence and have not established efficacy, optimal dosing, pharmacokinetics or a therapeutic window. Methylglyoxal itself is not an approved anticancer therapy. Historical clinical studies of methylglyoxal-bis-guanylhydrazone must not be interpreted as trials of methylglyoxal because it is a distinct pharmacological compound.</p>
<p><b>Safety / translation constraint:</b> MGO is intrinsically electrophilic and cytotoxic. Excess endogenous MGO is associated with AGE formation, endothelial dysfunction, diabetic complications, neurotoxicity and DNA adduct formation. Recent human PBK modeling indicates that endogenous or sufficiently high systemic exposure can raise genotoxicity and neurotoxicity concerns. This substantially limits extrapolation of tumor-selective high-dose in-vitro effects to systemic human administration.</p>
<h3>Methylglyoxal Cancer Mechanisms</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>GLO1 and Glyoxalase System</td>
<td>GLO1 dependence ↑; MGO detoxification ↓ when system overwhelmed or inhibited</td>
<td>Essential detoxification pathway</td>
<td>R–G</td>
<td>Dicarbonyl stress ↑</td>
<td>Central therapeutic axis. Highly glycolytic tumors may overexpress GLO1 to survive increased endogenous MGO production.</td>
</tr>
<tr>
<td>2</td>
<td>GAPDH and Glycolysis</td>
<td>GAPDH ↓; glycolysis ↓</td>
<td>Variable; toxicity emerges as exposure rises</td>
<td>R</td>
<td>ATP production ↓</td>
<td>Selective GAPDH inactivation has been reported in malignant tissues, but tumor selectivity should not be assumed universally.</td>
</tr>
<tr>
<td>3</td>
<td>Mitochondrial Complex I and OXPHOS</td>
<td>Complex I ↓; respiration ↓; NADH oxidation ↓</td>
<td>Often less affected in experimental models; cardiac mitochondria may be susceptible</td>
<td>R</td>
<td>Energetic collapse ↑</td>
<td>Reported in leukemia, sarcoma and other malignant-cell preparations. Tissue selectivity is model-dependent.</td>
</tr>
<tr>
<td>4</td>
<td>ATP Depletion</td>
<td>ATP ↓</td>
<td>↓ at sufficiently toxic exposure</td>
<td>R–G</td>
<td>Cell viability ↓</td>
<td>Combined suppression of glycolysis and mitochondrial respiration can profoundly reduce cancer-cell ATP.</td>
</tr>
<tr>
<td>5</td>
<td>Mitochondrial ROS and Oxidative Stress</td>
<td>ROS ↑</td>
<td>ROS ↑ (dose-dependent)</td>
<td>R</td>
<td>Oxidative injury ↑</td>
<td>ROS scavenging can attenuate MGO-induced apoptosis, supporting a mechanistic role rather than ROS being merely a by-product.</td>
</tr>
<tr>
<td>6</td>
<td>Mitochondrial Apoptosis</td>
<td>Bax ↑; Bcl-2 ↓; cytochrome-c release ↑; apoptosis ↑</td>
<td>Apoptosis ↑ at toxic exposure</td>
<td>G</td>
<td>Programmed cell death ↑</td>
<td>Well demonstrated in cancer-cell models including triple-negative breast cancer.</td>
</tr>
<tr>
<td>7</td>
<td>Protein and DNA Glycation</td>
<td>MG adducts ↑; proteotoxic stress ↑; DNA damage ↑</td>
<td>MG adducts ↑; DNA damage ↑</td>
<td>G</td>
<td>Replication and cellular stress ↑</td>
<td>Not tumor-specific. This mechanism contributes both to anticancer cytotoxicity and systemic safety concerns.</td>
</tr>
<tr>
<td>8</td>
<td>PI3K AKT Survival Signaling</td>
<td>p-AKT ↓ (model-dependent)</td>
<td>Context-dependent</td>
<td>G</td>
<td>Survival signaling ↓</td>
<td>Observed during cytotoxic MGO exposure; likely downstream or cooperative rather than the initiating mechanism.</td>
</tr>
<tr>
<td>9</td>
<td>NF-κB Survival Signaling</td>
<td>NF-κB nuclear signaling ↓ at cytotoxic exposure</td>
<td>Context-dependent</td>
<td>G</td>
<td>Pro-survival signaling ↓</td>
<td>High MGO can suppress NF-κB in cancer models, whereas chronic AGE-RAGE signaling can activate NF-κB. Direction is concentration- and context-dependent.</td>
</tr>
<tr>
<td>10</td>
<td>AGE RAGE Inflammatory Signaling</td>
<td>AGE formation ↑; RAGE signaling ↑ (context-dependent)</td>
<td>AGE formation ↑; RAGE signaling ↑</td>
<td>G</td>
<td>Inflammation and cellular stress ↑</td>
<td>Important dual-role mechanism. Chronic modest MGO elevation may be tumor-promoting rather than therapeutic.</td>
</tr>
<tr>
<td>11</td>
<td>MAPK Signaling</td>
<td>↑ or mixed (context-dependent)</td>
<td>↑ or mixed</td>
<td>R–G</td>
<td>Stress and inflammatory signaling</td>
<td>Direction varies according to cell type, MGO concentration and whether direct MGO toxicity or AGE-RAGE signaling predominates.</td>
</tr>
<tr>
<td>12</td>
<td>GSH Dependence</td>
<td>GSH utilization ↑; detoxification capacity can become limiting</td>
<td>GSH-dependent detoxification ↑</td>
<td>R</td>
<td>MGO clearance</td>
<td>GSH is an obligatory component of the principal glyoxalase detoxification pathway; severe MGO stress can therefore intersect strongly with cellular redox capacity.</td>
</tr>
<tr>
<td>13</td>
<td>GABA-A Receptor</td>
<td>Not a major cancer mechanism</td>
<td>GABA-A activation ↑</td>
<td>P</td>
<td>Neuronal inhibition ↑</td>
<td>MGO is an endogenous partial GABA-A agonist. High exposure can produce locomotor depression, ataxia and hypothermia in animal models.</td>
</tr>
<tr>
<td>14</td>
<td>Clinical Translation Constraint</td>
<td>Effective experimental intracellular exposure may be difficult to reproduce systemically</td>
<td>AGE formation, neurotoxicity, endothelial toxicity and genotoxicity ↑ with excessive exposure</td>
<td>R–G</td>
<td>Therapeutic window constrained</td>
<td>Rapid metabolism and high chemical reactivity, together with substantial overlap between anticancer mechanisms and normal-tissue toxicity, remain major barriers. Human efficacy is unproven.</td>
</tr>
</tbody>
</table>
<p>P: 0–30 min R: 30 min–3 hr G: >3 hr</p>